CRISPR Epigenetic Switch Reverses Coronary Atherosclerosis in Non-Human Primate Trials
Medical laboratory researcher conducting molecular cellular analysis
SINGAPORE — BOSTON — In results described by cardiologists as a historic leap forward for preventative medicine, international researchers published findings demonstrating the complete reversal of established arterial plaque in non-human primate models. Rather than cutting DNA strands, the therapy utilizes transient epigenetic editing to quiet lipid-storing inflammatory receptors in vascular endothelium.
Dissolving Plaque Through Epigenetic Reprogramming
Atherosclerosis has historically been considered an irreversible progressive disease managed primarily through cholesterol-lowering statins and invasive vascular stenting. In the eight-month trial, intravenous delivery of targeted lipid nanoparticles silenced...